Aspen Pharmacare Holdings (APN) Stock Overview
Manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for APN from our risk checks.
APN Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R93.87 |
| 52 Week High | R185.95 |
| 52 Week Low | R90.70 |
| Beta | 0.32 |
| 1 Month Change | -1.20% |
| 3 Month Change | -7.97% |
| 1 Year Change | -44.56% |
| 3 Year Change | -30.79% |
| 5 Year Change | -26.90% |
| Change since IPO | 10,512.54% |
Recent News & Updates
We Discuss Why Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation May Be Closely Reviewed
Nov 28
Investors Aren't Buying Aspen Pharmacare Holdings Limited's (JSE:APN) Revenues
Nov 18Recent updates
We Discuss Why Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation May Be Closely Reviewed
Nov 28Investors Aren't Buying Aspen Pharmacare Holdings Limited's (JSE:APN) Revenues
Nov 18Aspen Pharmacare Holdings' (JSE:APN) Dividend Is Being Reduced To ZAR2.11
Sep 06Aspen Pharmacare Holdings Limited's (JSE:APN) Share Price Could Signal Some Risk
Aug 04Aspen Pharmacare Holdings Limited (JSE:APN) Shares May Have Slumped 35% But Getting In Cheap Is Still Unlikely
Apr 24
Commercial Pharma And GLP-1 Expansion Will Empower Future Progress
Steady commercial pharma growth through strategic market focus in China and Russia enhances revenue stability.Does Aspen Pharmacare Holdings (JSE:APN) Have A Healthy Balance Sheet?
Mar 06We Think Shareholders May Want To Consider A Review Of Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Package
Nov 29Aspen Pharmacare Holdings Limited (JSE:APN) Not Lagging Market On Growth Or Pricing
Nov 09Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings
Oct 10Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Shareholder Returns
| APN | ZA Pharmaceuticals | ZA Market | |
|---|---|---|---|
| 7D | -1.0% | -0.04% | 0.8% |
| 1Y | -44.6% | -10.1% | 23.6% |
Return vs Industry: APN underperformed the ZA Pharmaceuticals industry which returned -10.1% over the past year.
Return vs Market: APN underperformed the ZA Market which returned 23.6% over the past year.
Price Volatility
| APN volatility | |
|---|---|
| APN Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in ZA Market | 10.7% |
| 10% least volatile stocks in ZA Market | 2.7% |
Stable Share Price: APN has not had significant price volatility in the past 3 months compared to the ZA market.
Volatility Over Time: APN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1850 | 9,343 | Stephen Saad | www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands.
Aspen Pharmacare Holdings Limited Fundamentals Summary
| APN fundamental statistics | |
|---|---|
| Market cap | R41.68b |
| Earnings (TTM) | -R1.08b |
| Revenue (TTM) | R43.36b |
Is APN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APN income statement (TTM) | |
|---|---|
| Revenue | R43.36b |
| Cost of Revenue | R24.31b |
| Gross Profit | R19.05b |
| Other Expenses | R20.14b |
| Earnings | -R1.08b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 43.94% |
| Net Profit Margin | -2.50% |
| Debt/Equity Ratio | 42.0% |
How did APN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/14 21:06 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aspen Pharmacare Holdings Limited is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rendani Magalela | Absa Bank Limited |
| Andre Bekker | Arqaam Capital Research Offshore S.A.L. |
| Boitshepo Seruwe | Avior Capital Markets |